Abstract
Molecular pathologic testing plays an important role for the diagnosis, prognostication and decision of treatment strategy in lymphoproliferative disease. Here, we briefly review the molecular tests currently used for lymphoproliferative disease and those which will be implicated in clinical practice in the near future. Specifically, this guideline addresses the clonality test for B- and T-cell proliferative lesions, molecular cytogenetic tests for malignant lymphoma, determination of cellof- origin in diffuse large B-cell lymphoma, and molecular genetic alterations incorporated in the 2016 revision of the World Health Organization classification of lymphoid neoplasms. Finally, a new perspective on the next-generation sequencing for diagnostic, prognostic, and therapeutic purpose in malignant lymphoma will be summarized.
| Original language | English |
|---|---|
| Pages (from-to) | 224-241 |
| Number of pages | 18 |
| Journal | Journal of Pathology and Translational Medicine |
| Volume | 51 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2017 May 1 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2017 The Korean Society of Pathologists/The Korean Society for Cytopathology.
Keywords
- Clonality test
- Fluorescence
- Gene translocation
- In situ hybridization
- Lymphoproliferative disorders
- Malignant lymphoma
- Molecular
- Molecular diagnostics
- Next-generation sequencing
- Pathology
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Histology